Methods for production of unstructured recombinant polymers and uses thereof

• US 7,846,445 B2
• Filed: 03/06/2007
• Issued: 12/07/2010
• Est. Priority Date: 09/27/2005
• Status: Active Grant

• Current Assignee: Amunix Pharmaceuticals, Inc. (Sanofi )
• Original Assignee: Amunix Operating Inc.
• Inventors: Schellenberger, Volker, Wang, Chia-wei, Stemmer, Willem P., Crameri, Andreas, Scholle, Michael D., Popkov, Mikhail, Gordon, Nathaniel C.
• Primary Examiner(s): Wessendorf; Teresa D.
• Application Number:
  US11/715,296
• Publication Number:
  US 20080286808A1
• Time in Patent Office: 1,372 Days
• Field of Search: 424/180.1, 424/179.1, 424/178.1
• US Class Current: 424/180.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/001 by chemical synthesis
• CPC Class Codes: C07K 14/415 from plants
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators
• CPC Class Codes: C07K 2319/21 containing a His-tag
• CPC Class Codes: C07K 2319/43 containing a FLAG-tag
• CPC Class Codes: C12N 15/1044 Preparation or screening of libraries displayed on scaffold proteins
• CPC Class Codes: C12N 2795/14011 ssDNA Bacteriophages
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92
• CPC Class Codes: G01N 33/6845 Methods of identifying protein-protein interactions in protein mixtures

Abstract

The present invention provides methods of using unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities, and the uses thereof. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.

Claims

1. A method of increasing serum secretion half-life of a protein, comprising:

fusing an N- and/or C-terminus of said protein with at least one unstructured recombinant polypeptides (URPs) to create a monomeric fusion protein, wherein an individual URP comprises at least about 40 contiguous amino acids, and wherein

(a) the sum of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues contained in the URP, constitutes at least 80% of the total amino acids of the URP, and the remainder, when present, consists of arginine or lysine, and the remainder does not contain methionine, cysteine, asparagine, and glutamine, wherein said UPR comprises at least three different types of amino acids selected from glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P);

(b) at least 50% of the at least 40 contiguous amino acids in said URP are devoid of secondary structure as determined by Chou-Fasman algorithm;

(c) wherein the URP has a Tepitope score less than −

4;

and wherein

the monomeric fusion protein has at least a 2-fold increase in apparent molecular weight of the fusion protein as compared to the protein lacking said URP, wherein the apparent molecular weight is approximated by size exclusion chromatography, and wherein the fusion protein exhibits an increased half-life as compared to the protein lacking said URP.

2. The method of claim 1 wherein said fusing increases serum secretion half-life of the protein by at least 2-fold.

3. The method of claim 1, wherein glycine residues contained in the URP constitute at least 50% of the total amino acids of the URP.

4. The method of claim 1, wherein the sum of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E), and proline (P) residues contained in the URP, constitutes at least 90% of the total amino acids of the URP.

5. The method of claim 1, wherein one type of the amino acids selected from the group consisting of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E), and proline (P) constitutes at least 20% of the total amino acids of the URP.

6. The method of claim 1, wherein the URP comprises more than 100 contiguous amino acids.

7. The method of claim 1, wherein the therapeutic protein is selected from the group consisting of cytokines, growth factors, enzymes, receptors, microproteins, hormones, erythopoetin, adenosine deiminase, asparaginase, arginase, interferon, growth hormone, growth hormone releasing hormone, G-CSF, GM-CSM, insulin, hirudin, TNF-receptor, uricase, rasburicase, axokine, RNAse, DNAse, phosphatase, pseudomonas exotoxin, ricin, gelonin, desmoteplase, laronidase, thrombin, blood clotting enzyme, VEGF, protropin, somatropin, alteplase, interleukin, factor VII, factor VIII, factor X, factor IX, dornase, glucocerebrosidase, follitropin, glucagon, thyrotropin, nesiritide, alteplase, teriparatide, agalsidase, laronidase, and methioninase.

8. The method of claim 1, wherein the URP comprises more than 200 contiguous amino acids.

9. The method of claim 1, wherein the URP comprises more than 400 contiguous amino acids.

10. The method of claim 1, wherein one type of amino acid is no more than 30% of the total amino acids of the URP.